

Prescription Drug Affordability Board

Data Collection Background

Senate Bill 5532 (2022)

▶ History

- ▶ Passed during the 2022 Legislative session
- ▶ Based on the National Academy for State Health Policy (NASHP) model legislation, amended during the process

▶ Board

- ▶ Five-member board appointed by governor
- ▶ Serve five-year terms
- ▶ Conflicts of interest prohibited

Eligible Drug List

- ▶ RCW 70.405.030
- ▶ Drugs subject to the purview of the Board:
 - ▶ Brand names and biologics
 - ▶ Have a wholesale acquisition cost (WAC) of \$60,000 or more for a course of treatment less than one year
 - ▶ Price increase of 15 percent per year or 50 percent over three years
 - ▶ Biosimilars with initial acquisition cost not at least 15 percent lower than the reference biological product
 - ▶ Generics with a wholesale acquisition cost of \$100 or more for a 30-day supply that increased 200 percent or more in the previous year

Affordability reviews

- ▶ RCW 70.405.040
- ▶ Board may conduct affordability reviews of up to 24 drugs per year from the eligible drug list
- ▶ Must determine whether the drug led or will lead to excess costs to patients
- ▶ The board may examine publicly available information as well as collect confidential and proprietary information from the prescription drug manufacturers and other relevant sources.
- ▶ Manufacturers must submit all requested information to the board within 30 days of the request

Affordability reviews

▶ Must consider:

- ▶ Relevant price factors
- ▶ Average patient costs
- ▶ Effects on access
- ▶ Orphan drug status
- ▶ Patient assistance programs
- ▶ Therapeutic alternatives
- ▶ Input from patients and medical experts

▶ May consider:

- ▶ Life-cycle management
- ▶ The average cost of the drug in the state
- ▶ Market competition and context
- ▶ Projected revenue
- ▶ Off-label usage of the drug
- ▶ Any additional factors identified by the board.

Current Updates

- ▶ Identified a list of 294 drugs which meet the drug review criteria outlined in the legislation
- ▶ Created a dashboard to show relevant data required for selection of drugs for a drug review
- ▶ Worked with our board to rank and weight the data metrics to prioritize drugs for selection
- ▶ Finalizing some additional dashboard requests by the board before they select any drugs
- ▶ Currently developing data forms to help gather required data for drug reviews when drugs are selected.

Next Steps

- ▶ Seeking feedback and collaboration with our industry partners
- ▶ Please submit written comments by March 14th
- ▶ Email: HCA_WA_PDAB@hca.wa.gov